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Introduction
Interleukin-10 (IL-10) was first described as a product of T helper 2 (Th2) cells that inhibited cytokine production by T helper 1 cells (Th1; refs. 1, 2). In addition to Th2 cells, IL-10 is produced by different T-cell subsets (including Th1 cells) (3), B cells, myeloid antigen-presenting cells (APC; refs. 1, 2), keratinocytes (4) , and epithelial cells (5) . IL-10 has been thought to be largely immunosuppressive, enacting multiple inhibitory effects on APCs. IL-10 restrains antigen presentation via its inhibition of MHC and costimulatory B7 family member molecules (1, 2) , stimulates inhibitory B7 family members (6) (7) (8) , downregulates IL-12 production, and inhibits dendritic cell (DC) differentiation and maturation (9) . Therefore, most attention has been devoted to the immunosuppressive roles of IL-10 in a variety of experimental settings, particularly in infectious disease models (9) (10) (11) . In addition to immunosuppressive effects, IL-10 also exerts some immunostimulatory effects, such as promoting the generation of cytotoxic T lymphocytes, activating B cells (1, 3, 12) , and upregulating a small number of genes in TLR-activated macrophages and DCs (13) .
Although the underlying mechanisms are poorly understood, the stimulatory effects of IL-10 have also been observed in the context of tumor. Transfection of tumor cells with IL-10 or systemic IL-10 administration significantly suppressed tumor growth and led to tumor rejection (14) (15) (16) (17) . These data suggest that the biological activities of IL-10 in tumor pathology may be highly context-dependent.
Over the past few years, we and others have achieved important insights into tumor immunopathogenesis in patients with cancer. We and others have shown that the tumor microenvironment is comprised of regulatory T (Treg) cells (18, 19) , myeloid-derived suppressor cells (MDSC; refs. [20] [21] [22] [23] [24] [25] [26] [27] [28] and dysfunctional APCs (6, 7, 29, 30 ) that form a suppressive network to defeat tumor-specific immunity and promote tumor growth. Because IL-10 is functionally linked to Treg cells and MDSCs (15) (16) (17) , we revisited the role of IL-10 in tumor pathology in this study. We have shown that IL-10 inhibits inflammatory cytokine production, hampers the development of MDSCs and Treg cells in the tumor microenvironment, and retards tumor development, growth, and metastasis.
Methods

Tumor models
Six-to 8-week-old C57BL/6 mice (strain #000664) were purchased from the Jackson Laboratory. IL-10 À/À mice (strain #2251) and IL-1R À/À mice (strain #3245) were purchased from the Jackson Laboratory (Jackson Laboratory, Maine) and bred in-house. The mice were maintained in specific pathogen-free conditions. This research was approved by the committee on Use and Care of Animals at the University of Michigan. 
AOM/DSS treatment
Mice were given 10 mg/kg azoxymethane (AOM; Sigma) via intraperitoneal injection. Five days later, they were allowed free access to water containing 2% dextran sodium sulfate (DSS; MP Biomedicals/Fisher) for 5 days, followed by 16 days of regular water. This cycle was repeated twice and mice were sacrificed 2 weeks after the end of the last DSS cycle or at the end of 9 weeks. Colons were harvested, flushed of feces, and slit open longitudinally to count tumors with the aid of a magnifier.
IL-1Ra treatment
The human recombinant IL-1 receptor antagonist Anakinra (Kineret) was administered at 150 mg/kg to mice intraperitoneally for 5 days before tumor inoculation and each day thereafter for 3 weeks. Mice not receiving anakinra were injected with PBS vehicle.
Flow cytometry analysis
Single-cell suspensions were made from spleen, tumordraining lymph nodes (TDLN), and tumor. Cells were labeled with fluorescence-conjugated antibodies to CD45 (Invitrogen), CD4, CD8, Gr-1, CD11b, CD90, CD115 (all eBioscience), IFNg, MHC I, CD19 (all BD Pharmingen), and/or Foxp3 (eBioscience). For cytokine profiles, the cells were stimulated with 50 ng/mL PMA (Sigma) and 1 mmol/L Ionomycin (Sigma-Aldrich) for 4 hours in the presence of GolgiPlug and GolgiStop (BD Biosciences). Cells were first stained extracellularly with specific antibodies, then fixed and permeabilized with Fix/Perm solution (eBioscience) and finally, stained intracellularly with specific antibodies. Samples were acquired on a special order LSR II flow cytometer (BD Biosciences), and data were analyzed with DIVA software (BD Biosciences; refs. 7, 18).
Immunofluorescence analysis
Immunofluorescence analysis was done as previously described (7, 18) . Briefly, harvested tissues were frozen in OCT and then fixed with paraformaldehyde. Permeabilized tissues were stained with rat anti-mouse CD8 (1:50; BD Pharmingen), rat anti-mouse CD31 (1:00; BD Pharmingen), and/or rabbit anti-mouse Foxp3 (1:500; Abcam), followed by goat anti-rat and goat anti-rabbit secondaries conjugated to Alexa Fluor 488 and Alexa Fluor 568, respectively (both 1:2000; Molecular Probes/Invitrogen). Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI; Molecular Probes/Invitrogen). Fluorescent images were acquired on a fluorescence microscope (Leica) and analyzed by ImagePro Plus software.
MDSC suppression and Treg induction
For the immunosuppressive assay, MDSCs were isolated and sorted with a high-speed sorter (FACSAria; BD) from tumor in tumor-bearing mice, and responder T cells were isolated from spleen in normal wild-type (IL-10 þ/þ ) mice. Normal spleen T cells were stimulated for 3 days with anti-CD3 (2.5 mg/mL) and anti-CD28 ( . Cytokine transcripts were detected by real-time reverse transcriptase PCR as previously described (33) . Gene-specific primer pairs and Fast SYBR Green Master Mix (Applied Biosystems) were used in a Multiplex instrument (Eppendorf). Data analysis is based on the C t method, with normalization of raw data to a housekeeping gene (HPRT).
Statistics
Most experiments were evaluated using the Mann-Whitney test, with P < 0.05 considered significant. Some cases were evaluated with Student's t test and quadratic regression model, also with P < 0.05 considered significant. Statistics were carried out in the GraphPad Prism program suite (GraphPad Software, Inc.) and Statistica program suite (StatSoft).
Results
IL-10 deficiency increases tumor incidence, growth, and foci formation
The immune-inhibitory role of IL-10 has been well defined in numerous experimental settings. However, the in vivo effects of endogenous IL-10 on tumor immune responses and tumorigenesis are not well understood. We compared tumor incidence, growth, and foci formation in IL-10-deficient (IL-10 Fig. 1D . We further examined the effect of endogenous IL-10 on the development of mouse lung metastatic foci. To this end, MCA310, a methylcholanthrene-induced sarcoma, was intravenously injected into the 2 groups of mice. IL-10 À/À mice had more tumor foci in the lungs than IL-10 þ/þ mice (Fig. 1E) . Thus, IL-10 deficiency increases tumor incidence, growth, and lung foci formation.
IL-10 deficiency increases Treg cells in the tumor
We next investigated the well-defined immunosuppressive immune cell subsets in the tumor microenvironment, including Treg cells. The percentages of intratumoral Treg cells during the course of MC38 tumor development were higher in IL-10 À/À mice as compared with their wild-type counterparts beginning on day 6 ( Fig. 2A and B ). There was a significant correlation between tumor weight and percentage of intratumoral Treg cells in both IL-10 þ/þ and IL-10 À/À mice. Furthermore, a quadratic regression analysis revealed that Treg cell levels were higher in IL-10 À/À mice than IL-10 þ/þ mice across different tumor volumes (Fig. 2C) . Interestingly, although Treg populations do not differ in the spleens and lymph nodes of unchallenged, tumor-free mice (Supplementary Fig. S1A and B), they were considerably increased in the TDLNs and spleen of tumor-bearing mice on days 12 and 15 ( 
IL-10 deficiency increases MDSC in the tumor
In addition to Treg cells, MDSCs are also an important immunosuppressive component in tumor-bearing hosts. We observed that intratumoral Gr-1 þ CD11b þ MDSCs were consistently increased in IL-10 À/À mice in comparison with IL-10 þ/þ mice throughout the duration of tumor growth (Fig. 3A, Supplementary Fig. S2A ). Similar to intratumoral Treg cells, a quadratic regression analysis revealed that intratumoral MDSC levels were higher in IL-10 À/À mice than IL-10 Fig. S4 ).
We further examined the roles of MDSCs on T-cell activation and tumor growth. In an in vitro immune suppression assay, similar to IL-10 þ/þ MDSCs, tumor-derived IL-10 À/À MDSCs suppressed T-cell proliferation in a dose-dependent manner (Fig. 3C ). To directly test the effects of MDSCs in vivo, we completed immune cell adoptive transfusion experiments. We initially irradiated IL-10 þ/þ mice and infused them with total (Fig. 3D) , which is in line with our observations of nonirradiated mice (Fig. 1B-D) , we showed that after MDSC depletion, tumor volumes were similar in irradiated mice receiving either IL-10 À/À or IL-10 þ/þ immune cells (Fig. 3D) .
The data indicated that MDSCs serve as important suppressive components of the IL-10 À/À immune system in vivo.
We then hypothesized that MDSCs might induce Treg cells in tumor-bearing mice, as previously reported (22) . In support of this, we observed that both tumor-derived IL-10 À/À and IL-10 þ/þ MDSCs from MC38-bearing mice induced Treg cells. However, Treg cells were more efficiently induced by IL-10 À/À MDSCs, as compared with IL-10 þ/þ MDSCs (Fig. 3E) . Altogether, our results indicated that IL-10 deficiency increases Treg cells and MDSCs and suggest that increased MDSCs may induce Treg cells in tumor-bearing mice.
IL-1 contributes to increased tumor growth in IL-10 À/À mice
After showing the cellular mechanisms which may contribute to increased tumor incidence, growth, and foci formation in IL-10 À/À mice, we further examined the relevant molecular patterns. We showed that myeloid cells from tumor-free mice expressed higher levels of IL-1a and IL-1b in IL-10 À/À than IL-10 þ/þ mice (Fig. 4A) . We then investigated the role of IL-1 in tumor growth in IL-10 À/À mice. Anakinra, the recombinant human IL-1 receptor antagonist (IL-1Ra), has shown biological efficacy in mice (35) . We treated tumor-bearing IL-10 À/À and IL-10 þ/þ mice with anakinra or vehicle over a period of 3 weeks and observed that IL-10 À/À mice treated with anakinra had reduced tumor burden (Fig. 4B) . Interestingly, tumor growth was comparable in IL-10 þ/þ mice treated with anakinra and those treated with PBS vehicle (Fig. 4C) . In further support of the relevance of IL-1, we showed that tumor volume 
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þ T cells were also increased in mice treated with anakinra (Fig. 5B) . Although the levels of MDSCs were comparable in the 2 groups (not shown), the numbers of tumor-infiltrating Treg cells were reduced in mice treated with anakinra (Fig. 5C ). Furthermore, tumor microvessel intensity and size (Fig. 5D) were reduced by anakinra treatment. Altogether, the data suggested that IL-1 blockade promotes tumor immune surveillance and reduces tumor angiogenesis.
Discussion
IL-10 has been thought to be largely immune suppressive. However, to our surprise, chemically induced tumor incidence, transplanted tumor growth, and lung foci formation are increased in IL-10 À/À mice. This is associated with a number (15) (16) (17) . However, the underlying mechanisms by which IL-10 mediates suppression of tumor growth despite its defined immune-inhibitory functions remained elusive. In addition to regulating immunosuppressive components, we do not rule out the possibility that IL-10 directly affects T-cell activation. In line with this, it has been reported that IL-10 may promote CD8 differentiation and expansion (36) (37) (38) . In fact, humans treated with IL-10 showed a reduction of IL-1 and increased IFNg (39, 40) . Our studies suggest that the biological activities of IL-10 may be highly context dependent and vary in the presence of different cellular targets, phases of immune responses, and disease model systems. A similar example of this phenomenon is MyD88 signaling, which has been implicated in the promotion of cancer in several mouse carcinogenesis models. However, under chronic colitis conditions induced by DSS-induced mucosal damage, MyD88 has a protective role in colon cancer (12) .
Given that IL-10 can be immune stimulatory and inhibitory, the balance of these effects may determine whether IL-10 is beneficial or detrimental in a given model system and/or disease stage. The immune-regulatory roles of IL-10 are prominently defined in infectious disease models. In these scenarios, APCs are the immediate and predominant targets of IL-10 (38). Infectious pathogens rapidly activate Toll-like receptors on APCs and induce antigen-specific T-cell priming. IL-10 inhibits the maturation and function of APCs via reduced MHC expression and IL-12 production, and subsequently suppresses T-cell priming and Th1-type responses (1, 2) . However, in a tumorbearing host, where there is no obvious acute phase of immune response (30), tumor-associated antigen (TAA)-specific priming may slowly occur, and IL-10 may preferentially target MDSCs and Treg cells before potent TAA-specific effector T-cell immunity is established (38) . This may partially explain the discrepancy of IL-10 biology in the literature.
It has been reported that IL-1 supports the development of MDSCs in tumor-bearing mice (25, 26, 41) The data suggests that IL-10 negatively regulates inflammatory cytokine production and directly inhibits inflammation-associated cancer development and growth. However, it is also possible that the reduced density of tumor microvessels may be due to the resulting enhanced T-cell immunity that includes the production of IFNg, a potent antiangiogenic factor (46) . Finally, we have shown that IL-1 blockade reduces tumor growth in IL-10 À/À mice. Accordingly, the levels of intratumoral Treg cells are reduced, and the numbers of tumorinfiltrating effector T cells and levels of effector cytokines are enhanced. Altogether, the increased tumor development, growth, and metastasis in IL-10 À/À mice result from multiple intertwined mechanisms: increased immunosuppression, enhanced inflammation, and possible reduced effector T-cell function and tumor trafficking in tumor-bearing hosts. In summary, contrasting the established views, we show that IL-10 is negatively linked to the development of immunosuppressive MDSCs and Treg cells, subverts tumor immune suppression, and in turn, contributes to reduced tumor development, growth, and metastasis. Our data indicate that the biological activities of IL-10 can be highly context dependent. 
